Last updated: 11/07/2018 01:07:58

Determination of alpha and beta blockade thresholds for carvedilol in comparison to 400mg labetalol in healthy volunteers.

GSK study ID
105517/155
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: Determination of alpha and beta blockade thresholds for carvedilol in comparison to 400mg labetalol in healthy volunteers.
Trial description: Determination of alpha and beta blockade thresholds for carvedilol in comparison to 400mg labetalol in healthy volunteers.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Why HJR, Richardson PJ. Effect of carvedilol on left ventricular function and mass in hypertension. J Cardiovasc Pharmacol 1992; 19 (Suppl 1): S50-S54.
Medical condition
Cardiovascular Disease
Product
carvedilol
Collaborators
Not applicable
Study date(s)
September 1989 to April 1990
Type
Not applicable
Phase
1

Participation criteria

Sex
Not applicable
Age
Not applicable
Accepts healthy volunteers
Not applicable

Trial location(s)

This study does not involve prospective enrollment of participants.

Study documents

Scientific result summary
Available language(s): English

If you wish to request for full study report, please contact - [email protected]

Results overview

Not applicable

Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1990-21-04

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website